For all patients:

Inability to decide to participate

Pregnancy or breath feeding

Hypersensitivity to any of the test drugs

stage 4 or 5 chronic kidney disease (DFG \<30 mL/min/1.73 m²)

For hydroxychloroquine arm:

Long QT syndrome or QTc space \>500 ms

Treatment with piperazine, halofantrine, dasatinib, nilotinib, citalopram, escitalopram, hydroxyzine, domperidone

Hepatic porphyria, retinopathy, known glucose-6-phosphate dehydrogenase deficiency,

Heart rate \<50/min

hypokaliemia \< 3.5 mmol/L

For diltiazem arm:

Heart rate\<40/min

Sinus bradycardia, second- or third-degree atrioventricular block

Left heart insufficiency with pulmonary stasis

Treatment with dantrolene, pimozide, dihydroergotamine, ergotamine, nifedipine, ivabradine, esmolol, bêta-blockers (bisoprolol, carvedilol, metoprolol, nebivolol), fingolimod

Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19

What this study is about